A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advancedor Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
|Astellas Pharma, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Cancers include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, kidney cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
|Are you at least 18 years old?
|Do you have a advanced solid tumor with a KRAS G12D mutation?